Skip to content
DE

ARA-290 (Cibinetide): How It Works, Clinical Studies, and Safety Questions

Clinical review pending

ARA-290 explained: proposed mechanisms, early neuropathy studies, mixed outcomes, safety findings, and verified regulatory limits.

A balance holds a bead chain on one side and a clear lens on the other.

ARA-290, also called cibinetide, is an experimental peptide designed to influence the body’s tissue protection and repair processes. Small clinical studies suggest that it may help with certain types of nerve damage. Whether those findings can lead to an effective treatment with an acceptable safety profile remains an open question. Large confirmatory studies are still needed.

ARA-290 is a research compound. The FDA lists its orphan indication for neuropathic pain in sarcoidosis as unapproved. The studies below describe research, not a way to treat yourself. Orphan drug designation provides development incentives; it is not drug approval. Source 1

At a glance

  • ARA-290 is a synthetic peptide containing 11 amino acids, derived from the helix B surface of erythropoietin. It was designed to protect tissue without stimulating red blood cell production.
  • Small phase 2 studies in sarcoidosis and type 2 diabetes found signals of changes in neuropathic symptoms and structural nerve markers. Not every outcome or dose showed an advantage over placebo.
  • The FDA orphan drug database records a September 13, 2011 designation for neuropathic pain in sarcoidosis, but no approval for that indication. The publications reviewed here do not include completed phase 3 evidence establishing efficacy.
  • The FDA’s May 14, 2026 list places cibinetide in Category 3 of bulk substances nominated for 503A compounding: the nomination lacked adequate supporting information. This is not approval, nor does it establish the legal status of every conceivable access route.
  • Claims that the developer closed in April 2026, explanations for that closure, and statements about the current status of all investigational new drug applications are not established by the primary sources checked here. They are therefore not presented as facts.
  • The correct compound reference is PubChem CID 91810664 for cibinetide. The earlier link to CID 16132310 refers to gardimycin and is retained only to document that misidentification. Neither record provides prescribing information. Source 1 Source 2 Source 3

Where ARA-290 came from and how it may work

Origins and discovery

ARA-290 emerged from Michael Brines and Anthony Cerami’s research into effects of erythropoietin, or EPO, that do not involve blood cell production. Leist and colleagues described a key observation in Science in 2004: chemically modifying EPO so that it no longer stimulated red blood cell production left its tissue-protective properties intact. This suggested that different receptor systems mediated the two functions. Leist et al., 2004

That observation led to a research goal: develop a molecule that activates EPO’s tissue-protective signaling without raising hematocrit, the proportion of blood volume occupied by red blood cells. ARA-290 grew out of that work. In a 2008 paper in the Proceedings of the National Academy of Sciences, Brines and colleagues described designing the compound around the helix B surface of the EPO molecule. They identified an 11-amino-acid sequence intended to selectively activate the tissue-protective receptor without binding to the conventional homodimeric EPO receptor. “Homodimeric” means that the receptor consists of two identical subunits. Brines et al., 2008

The innate repair receptor: the proposed mechanism

The conventional blood-forming pathway uses a homodimeric EPO receptor, EPOR–EPOR. It stimulates red blood cell production in bone marrow. ARA-290 research instead focuses on the other of the two EPO receptor systems described in this work.

The tissue-protective pathway is attributed to a heterodimeric complex made up of two different subunits: the EPO receptor and the beta-common receptor, also called CD131 or βcR. Brines and Cerami called this combination the innate repair receptor, or IRR. In a foundational 2004 PNAS study, Brines and colleagues showed that this EPOR/βcR heteroreceptor mediates EPO’s nerve- and cell-protective effects and can be distinguished pharmacologically from the blood-forming receptor. ARA-290 was developed to target the IRR. Brines et al., 2004

In a 2012 mechanistic review in Molecular Medicine, Brines and Cerami described how the IRR regulates the innate immune response during injury or metabolic stress and promotes signals that help cells survive. Proposed downstream effects include cellular survival signaling through the kinases Akt and ERK and reduced release of inflammatory signaling molecules. Activation of microglia and macrophages in nervous tissue may also be dampened. These immune cells participate in inflammation and repair. Brines and Cerami, 2012

Selectivity without stimulating red blood cell production

ARA-290 is intended to protect tissue without stimulating red blood cell production. Because it is designed to activate the IRR heterodimer rather than the homodimeric EPO receptor, it is described as nonerythropoietic: it should not promote red blood cell formation. Early animal studies and the clinical studies discussed here support that premise. The blood measures assessed during treatment remained stable.

In a 2014 review in Molecular Medicine, Brines described the IRR as a regulator of injury and healing. The review argued that activating it would avoid the cardiovascular and thrombotic risks that can result from the blood-forming effects of supraphysiologic EPO doses, including cardiovascular events and blood clots. That mechanistic argument does not establish that ARA-290 is broadly free of risk. Small, short human studies cannot reliably rule out these or other harms. Brines, 2014

A detailed 2015 mechanistic review by Collino and colleagues in Pharmacology & Therapeutics summarized the repair effects of the nonerythropoietic helix B peptide in preclinical models. The work covered effects on the nervous system, kidneys, heart, and metabolism. Collino et al., 2015

Pain signaling: peripheral nerves and the spinal cord

Rodent pain models have been used to study how ARA-290 affects peripheral nociceptors—nerve endings that detect potentially painful stimuli—and central pain processing. In Molecular Pain in 2014, Swartjes and colleagues reported lasting relief of neuropathic pain in rats alongside reduced activation of spinal cord microglia. The finding suggests a mechanism at the intersection of the nervous and immune systems that might extend beyond an immediate pain-relieving effect. Swartjes et al., 2014

An earlier paper from the same group, published in PLoS One in 2013, provided indirect evidence about this pathway. In a nerve injury model, ketamine did not relieve pain in mice genetically lacking the beta-common receptor CD131. This is consistent with the idea that IRR signaling is needed for at least some established pain-relieving mechanisms. Swartjes et al., 2013

Separately, Zhang and colleagues reported in Peptides in 2016 that ARA-290 could reduce pain in experimental models through effects on the TRPV1 channel. This ion channel helps peripheral nerves detect heat and inflammatory pain stimuli. A combination of central and peripheral mechanisms could help explain why different experimental models have suggested effects on neuropathic pain. Zhang et al., 2016

What human studies show

Phase 2 studies in sarcoidosis with small fiber neuropathy

The most extensive clinical data on ARA-290 come from a research program associated with Leiden University Medical Center in the Netherlands. Investigators studied the compound in people with sarcoidosis and small fiber neuropathy, or SFN.

SFN involves damage to small nerve fibers in the peripheral nervous system that have little or no myelin, the insulating covering around many nerve fibers. It can cause neuropathic pain, burning, and autonomic symptoms—problems with bodily functions that operate without conscious control. Standard nerve conduction tests can be normal because they primarily assess large nerve fibers. Sarcoidosis, a systemic inflammatory disease, is one of several possible causes.

In Pain Research and Treatment in 2012, Heij and colleagues reviewed pain and SFN in sarcoidosis. They also explained why existing treatments aimed at symptoms often provide inadequate relief. This helped establish the rationale for investigating the IRR as a potential way to alter the disease process. Heij et al., 2012

The program began with a randomized, double-blind, placebo-controlled pilot study by Heij and colleagues, published in Molecular Medicine in 2012. Twenty-two people with sarcoidosis and SFN symptoms completed the study: 12 received ARA-290 and 10 received placebo. The treatment was 2 mg of ARA-290 given intravenously, through a vein, three times a week for 4 weeks.

After four weeks, the Small Fiber Neuropathy Screening List, or SFNSL, symptom score improved by −11.5 ± 3.04 points with ARA-290 versus −2.9 ± 3.34 with placebo; the difference between groups was significant (P < .05). The ± values are standard errors of the mean. The paper also described improvements from baseline in the pain and physical functioning domains of the SF-36 questionnaire, both with P < .01. Its abstract reported changes of −23.4 ± 5.5 and −14.6 ± 3.9, respectively. Because the negative sign convention was not transparently explained, those figures are reproduced here as the publication’s reported values, not independently recalculated effect estimates. The comparison matters: these SF-36 findings describe changes within the treatment group, not automatically a significant advantage over placebo. Brief Pain Inventory scores and fatigue improved similarly in both groups; depressive symptoms did not change. Clinical and laboratory assessments raised no safety concerns in this small, four-week study. Source 1 Source 2

A 2014 clinical review by van Velzen and colleagues in Expert Opinion on Investigational Drugs summarized the early ARA-290 program in sarcoidosis-associated SFN. It placed the pilot findings in the context of drug development for this rare condition at the time. van Velzen et al., 2014

Dahan and colleagues published a central phase 2 study in Molecular Medicine in 2013. In this blinded, placebo-controlled trial, 36 people with sarcoidosis and confirmed SFN were randomly assigned to daily subcutaneous injections of 4 mg ARA-290 or placebo. Subcutaneous means under the skin. Treatment lasted 28 days.

After 28 days, the study reported changes in cold and heat pain thresholds (P = .027 and .032, respectively) and thermal discrimination threshold (P = .008) in the ARA-290 group compared with its own baseline. These findings reflect reduced thermal sensitivity at the hand, not a general improvement in the ability to distinguish temperatures; the mean values remained within the normal range. The P values are not direct between-group comparisons. Changes in corneal nerves and the 6-minute walk test were also reported. Source 1

Corneal confocal microscopy measures structural nerve features in the living eye. In the ARA-290 group, median nerve fiber area increased from baseline after 28 days, while the change with placebo was not significant. This type of marker adds information to symptom reports but does not by itself establish lasting clinical regeneration. The advantage on the SFNSL questionnaire remained apparent through week 16 after the study began. That does not mean every structural and functional outcome remained improved for 16 weeks. Pain intensity on the Brief Pain Inventory also improved similarly in both groups. Source 1

A randomized, placebo-controlled phase 2b study by Culver and colleagues in 2017 included 64 participants receiving 1, 4, or 8 mg of cibinetide daily for 28 days. At 4 mg, the placebo-corrected mean change in corneal nerve fiber area was 697 μm² (95% confidence interval, 159 to 1236; P = .012). The paper reports this outcome in μm², not μm²/mm². The corresponding values were 109 μm² (−429 to 647) at 1 mg and 431 μm² (−130 to 992) at 8 mg; both intervals included zero. The findings therefore do not establish a simple “higher dose, greater effect” relationship.

The 4-mg group also showed an increase in regenerating GAP-43-positive nerve fibers in the epidermis (P = .035), a signal of tissue repair. However, pain improved in all groups. In the subgroup with moderate to severe pain, the placebo-corrected pain difference at 4 mg was not statistically significant (P = .157). Structural changes and demonstrated pain relief relative to placebo therefore need separate interpretations. Source 1

These P values describe how compatible the results are with a null hypothesis of no effect of the kind being tested. They do not tell us the size of a benefit or, on their own, establish that a change matters in daily life or will be reproduced in larger studies.

A cross-cohort analysis by Brines and colleagues in Scientific Reports in 2018 examined corneal nerve fiber size as a marker for diagnosing SFN and assessing treatment response. Its findings supported the usefulness of the structural outcomes measured in the cibinetide studies. Brines et al., 2018

The program included the three randomized sarcoidosis trials described here, including the pilot study. It provides interesting phase 2 signals for symptoms and nerve structure. Results were not consistently positive, however: the measurement used, the dose, and the comparison with placebo all affect the conclusion.

Phase 2 findings in type 2 diabetes and diabetic neuropathy

A parallel clinical program investigated ARA-290 in type 2 diabetes with painful neuropathic symptoms. The double-blind, placebo-controlled trial by Brines and colleagues enrolled 49 people; 48 were included in the analysis after one withdrawal. Participants injected 4 mg of ARA-290 or placebo under the skin each day for 28 days, followed by another month of observation.

Reported changes included HbA1c (P = .002), PainDetect symptoms (P = .03), the cholesterol-to-HDL ratio (P = .039), and triglycerides (P = .043). HbA1c reflects average blood glucose exposure over preceding weeks; triglycerides are blood fats. Mean corneal nerve fiber density did not rise significantly in the full ARA-290 group. A significant increase from baseline appeared only in a post hoc subgroup analysis of people whose nerve fiber density had initially been low. Safety assessment should not stop at the reassuring abstract: the full report documented serious events, discussed below. Source 1

According to the methods section, HbA1c was a primary outcome, as were safety and several symptom questionnaires. Corneal nerve measurements were secondary outcomes, and the subgroup analysis mentioned above was post hoc. The small sample, short treatment period, and many measurements limit how widely the results can be applied. They provide a reason for further research, not a replacement for established diabetes care. Source 1

A separate open-label phase 2 pilot study by Lois and colleagues appeared in the Journal of Clinical Medicine in 2020. It tested daily subcutaneous injections of 4 mg cibinetide for 12 weeks in nine people with diabetic macular edema; eight completed the study. Macular edema is fluid accumulation in the part of the retina responsible for sharp central vision.

This study extended the research to a diabetes-related retinal condition. Among the eight completers, mean best-corrected visual acuity, central retinal thickness, central retinal sensitivity, and tear production did not improve after 12 weeks. The vision-related quality-of-life questionnaire improved slightly, and some individuals showed other changes. No serious adverse events or antibodies to cibinetide were observed. With no control group and so few participants, the study cannot establish either efficacy or comprehensive safety. Source 1

Limits of the evidence

The clinical studies are small: the sarcoidosis studies described here included 22, 36, and 64 participants. Early research was closely connected to Leiden, but the 2017 study was published as a multicenter trial and should not be described as an exclusively Dutch, single-center study. Several papers had personnel or financial connections to the developer. Independent confirmation, adequately sized samples, and longer follow-up would strengthen the evidence. Source 1

The publications reviewed here do not provide completed phase 3 evidence establishing efficacy. They also cannot establish that all development activity has ended or that no active investigational new drug application, or IND, remains. Public trial registries and company information require separate, date-specific assessment; they are not complete records of every regulatory proceeding.

The phase 2 findings provide proof of concept: early clinical indications that the research approach might work. Structural findings suggesting nerve regeneration are particularly relevant. They do not, however, provide sufficient evidence of efficacy by the standards required for drug approval.

Preclinical findings across organ systems

Kidney protection

The IRR is also expressed in the kidney, prompting preclinical studies of ARA-290 in kidney injury models. Van Rijt and colleagues published two complementary papers in the Journal of Translational Medicine in 2013. The first reported that ARA-290 reduced damage caused by interrupting and then restoring blood flow to the kidney. This ischemia–reperfusion injury can develop both during oxygen deprivation and when circulation returns. The second paper further described the compound’s kidney-protective properties in this type of model. van Rijt et al., 2013: Ischemia–reperfusion injury van Rijt et al., 2013: Kidney-protective properties

A more recent study by Ghassemi-Barghi and colleagues, published in Inflammation in 2023, reported protection against cisplatin-induced kidney injury through the EPOR/CD131 complex. Cisplatin is a chemotherapy drug, making the finding relevant to research on chemotherapy-related kidney damage. The work cited here is preclinical and does not establish a benefit in humans. Ghassemi-Barghi et al., 2023

Effects on the heart and immune system

In Frontiers in Cardiovascular Medicine, Winicki and colleagues reported that a non-blood-forming, EPO-derived peptide reduced cardiac inflammation and extended healthspan in animal models. Healthspan refers to time spent with preserved health or function; it does not necessarily mean a longer total lifespan. Winicki et al.

In Scientific Reports in 2017, Nairz and colleagues showed that cibinetide dampened innate immune cell functions and eased experimentally induced colitis in mice. Nairz et al., 2017

These findings suggest that the IRR may play a role in inflammatory injury and damage caused by insufficient blood flow across different organs. They fit the hypothesis that it provides a general signal for tissue protection and repair.

Brain ischemia and neurological autoimmune conditions

In CNS Neuroscience & Therapeutics in 2024, Wang and colleagues reported that ARA-290 protected brain tissue through the beta-common receptor in a model of ischemic stroke. An ischemic stroke occurs when a region of the brain receives insufficient blood flow. Wang et al., 2024

Earlier preclinical work examined inflammatory autoimmune conditions affecting the nervous system. In PLoS One in 2014, Liu and colleagues showed that ARA-290 reduced experimental autoimmune neuritis through inflammation suppression and tissue protection. This is a model of immune-mediated inflammation of peripheral nerves. Liu et al., 2014

Also in 2014, Chen and colleagues reported therapeutic effects in rats with experimental autoimmune encephalomyelitis, an inflammatory model of the central nervous system, in the Journal of Neuroimmunology. These findings support the mechanistic hypothesis. The studies cited here are preclinical and do not demonstrate treatment efficacy in humans. Chen et al., 2014

Wound healing and islet protection

In Biochimica et Biophysica Acta in 2018, Bitto and colleagues reported that cibinetide improved impaired wound healing in mice with genetic diabetes by activating the EPOR/beta-common receptor complex. Bitto et al., 2018

Two further papers examined ARA-290 in preclinical models of islet transplantation. Islets are the clusters of hormone-producing cells in the pancreas. In Transplantation in 2016, Watanabe and colleagues showed that ARA-290 inhibited macrophage activation and prevented damage to transplanted islets in the models studied. Watanabe et al., 2016

Yao and colleagues also reported in Transplantation, in 2020, that cibinetide improved the function of islet allografts in experimental research. “Allogeneic” means that transplanted cells come from another individual of the same species. The results fit the proposed role of the IRR in regulating inflammatory responses to injured or transplanted tissue. Yao et al., 2020

FDA classification

The FDA orphan drug record for neuropathic pain in sarcoidosis lists a designation dated September 13, 2011 and the status “Not FDA Approved for Orphan Indication.” Orphan designation offers development incentives for rare diseases; it does not establish an approved treatment. ARA-290 is discussed here as an experimental compound, not an FDA-approved therapy. Source 1

An IND concerns clinical investigation of an unapproved compound; NDA and BLA refer to applications for marketing approval. The current status of every such proceeding for ARA-290 cannot be fully established from the public sources checked here. Accordingly, this article does not claim that there is definitely no active IND or draw legal conclusions from an alleged company closure.

The FDA’s May 14, 2026 list places cibinetide (ARA-290) in Category 3: bulk substances nominated for the 503A list without adequate supporting information. It is not listed there in Category 1, which covers substances still under evaluation. A nomination or category assignment is not drug approval. Conditional enforcement policies concerning other substances would not constitute approval of cibinetide either. Source 1

Development status

The primary sources reviewed here do not confirm a company closure in April 2026 or financial or organizational reasons for development stopping. That account is therefore not presented as fact. The published phase 2 signals and IRR research remain scientifically relevant regardless. A company’s current status also does not answer the question of clinical efficacy.

Dahan and colleagues’ 2016 review, “Targeting the innate repair receptor to treat neuropathy,” summarizes the scientific rationale for this pathway. It cannot establish later company events or whether a development program has been taken over today. Source 1

What does this mean in practice?

ARA-290 is not an established, FDA-approved standard treatment. An online listing, a physician’s recommendation, or orphan designation does not replace approval or establish routine access to pharmaceutical-quality material. For U.S. compounding, the Category 3 classification described above is relevant; specific access questions require current legal and regulatory assessment.

Being unapproved does not mean being outside all FDA authority. Without assessing a specific product, it is also impossible to confirm its quality or judge every conceivable supply route. Publication of a clinical study does not make any product sold as ARA-290 equivalent to the material used in that study.

Safety: what is known and what is not

Clinical safety data from phase 2 studies

The three sarcoidosis studies described here had 22, 36, and 64 participants and treated them for four weeks or 28 days. The diabetes study enrolled 49 people, with 48 included in its analysis. These numbers include placebo groups; they are not totals of people exposed to ARA-290 alone. The macular edema pilot enrolled nine people, eight of whom completed 12 weeks of treatment. Describing the safety evidence simply as “about 150 treated people” or treatment lasting “4 to 28 days” would conceal these differences.

The small sarcoidosis studies reported largely reassuring short-term findings, including stable blood measures. In contrast, the full diabetes study report documented four serious events in the ARA-290 arm, two of which were initially considered possibly related. One participant with borderline kidney impairment worsened after an increase in the furosemide dose; the safety committee stopped ARA-290. Another developed severe cellulitis after treatment ended and suffered a fatal heart attack; the committee judged this event unrelated to treatment. These observations do not establish that ARA-290 caused the events, but they contradict a description in which all events were mild. Source 1

Additional human data come from a 2015 neuropsychological study by Cerit and colleagues in European Neuropsychopharmacology. It examined potentially antidepressant-like properties of ARA-290 in healthy volunteers. It adds short-term human observations, not proof that ARA-290 is an effective treatment for depression. Cerit et al., 2015

Small samples and short follow-up cannot characterize rare or long-term risks. Much also remains uncertain in people with substantial coexisting illness. Early publications mention additional dose-escalation and safety information, some described as unpublished developer data. That is not equivalent to a fully public, independently assessable dataset. This article does not claim to provide a complete account of every phase 1 result.

Risks of unregulated sources

This article does not provide a verified assessment of individual suppliers selling ARA-290 online. Relevant requirements would include traceable identity, purity, active ingredient content, sterility, stability, and manufacturing controls. A research label or a citation to clinical studies does not confirm those properties. At the same time, it would be inaccurate to assume that every product falls outside all regulatory authority.

Practical risks include contamination, an incorrect peptide amino acid sequence, and a concentration that differs from the label. Reliable pharmaceutical-quality manufacturing controls are needed to address them.

Who should not use ARA-290?

ARA-290 is not suitable for self-directed use. A clinical study needs the ethical and regulatory approvals applicable to it. Ethics approval alone is not a general authorization to administer an unapproved compound.

This assessment follows from its experimental status and limited clinical evidence. It does not depend on the unconfirmed claim that a sponsor has ended every regulatory proceeding. The study doses described here are not instructions for obtaining, preparing, or self-injecting the compound.

Several mechanistic considerations warrant particular caution. They identify unanswered safety questions, not a validated list of contraindications: there is no approved indication with corresponding prescribing information on which to base such a list.

  • In people with known or suspected cancer, proposed cell-survival and repair signaling raises theoretical questions. This does not establish a clinically demonstrated tumor-promoting effect.
  • The studies described do not provide adequate developmental or reproductive safety data for pregnancy or breastfeeding.
  • Pharmacokinetics and safety in severe kidney impairment are not adequately characterized. The kidney event in the diabetes study underscores the need for careful clinical assessment but does not establish specific kidney toxicity.
  • Under S0, the 2026 WADA Prohibited List prohibits pharmacological substances without approval from a governmental health authority for human therapeutic use, unless a subsequent category applies. ARA-290 is not explicitly named there; its derivation from EPO alone does not establish a verified S2 classification. Athletes need current guidance from their anti-doping authority and should not assume an experimental product is permitted.
  • Adequate interaction and safety data are lacking for anticoagulant use or clotting disorders. A design intended to avoid stimulating red blood cell production does not rule out other risks.
  • Online products can introduce additional hazards through incorrect identity, contamination, inadequate sterility, or inaccurate concentration. These risks are distinct from the safety of correctly manufactured research material. Source 1

When symptoms deserve medical attention

Established medical evaluation pathways are available for neuropathic pain, burning, or loss of sensation in the hands and feet. A primary care or neurological assessment can help identify the cause of peripheral neuropathy. Possible causes include vitamin B12 deficiency, diabetes, and autoimmune or inflammatory conditions such as sarcoidosis.

Blood tests are often part of that assessment, helping determine whether measurable abnormalities fit the symptoms. Further reading is available in the articles on compounds studied in neuropathy, including alpha-lipoic acid, and on metabolic health. Depending on the clinical question, measures of blood glucose regulation, inflammation, and organ function may help investigate the cause. Compounds studied in neuropathy, including alpha-lipoic acid Metabolic health

ARA-290 is scientifically interesting because the innate repair receptor offers a plausible approach to tissue protection. Phase 2 studies provide early clinical signals, including changes in structural nerve markers. Firmer conclusions require larger confirmatory trials, longer safety follow-up, and a clear connection between these markers and lasting benefits in everyday life. Mechanistic plausibility, a measurable biological effect, and an effective treatment represent different levels of evidence. For someone with symptoms, identifying the individual cause remains important.

Important safety information

ARA-290 is an experimental compound. The FDA orphan indication checked here is unapproved, and cibinetide appears in Category 3 of the FDA’s May 14, 2026 503A list. That does not establish the status of all IND, NDA, or BLA proceedings or provide a blanket legal judgment about every product. The alleged company closure is not established here as fact.

Published human studies are mostly small and short. Stable blood measures fit the nonerythropoietic design but do not establish general safety. Serious events were also reported in the diabetes study, with different assessments of their possible relationship to the compound. Long-term risks and rare events remain inadequately characterized.

Experimental administration belongs in a properly approved and supervised research setting or another lawfully authorized clinical setting, not self-experimentation. The questions concerning cancer, pregnancy, breastfeeding, kidney function, anticoagulants, and anti-doping are not a validated contraindication list from approved prescribing information.

This article confirms neither pharmaceutical quality nor a lawful access route for any specific online product. Lack of approval and unverified quality do not mean that the FDA or other authorities have no jurisdiction. Product identity and legal status require separate assessment.

This article is for information and education only. It does not provide medical advice, a diagnosis, or treatment instructions. Involve a qualified health professional in decisions about your health.

Frequently asked questions

Is ARA-290 FDA-approved?

The FDA database lists the orphan indication for neuropathic pain in sarcoidosis as unapproved. The September 13, 2011 designation is a development incentive, not drug approval. The sources reviewed here do not establish an approved ARA-290 therapy.

The FDA’s May 14, 2026 list places cibinetide in Category 3 of nominations for 503A bulk substances because supporting evidence was inadequate. This is not authorization for general treatment or a positive quality assessment of any product offered for sale.

Whether a particular activity or access route is lawful depends on the product, purpose, regulatory requirements, and applicable law. An unconfirmed statement about an IND cannot establish a universal ban on every possible route. Equally, an online listing does not mean that authorities have permitted its use.

What is the innate repair receptor?

The innate repair receptor, or IRR, is a heterodimeric receptor complex formed from the erythropoietin receptor EPOR and the beta-common receptor CD131, also called βcR. It contains two different subunits. The conventional homodimeric EPO receptor, by contrast, has two identical subunits and stimulates red blood cell production.

In a 2004 PNAS paper, Brines and colleagues described the IRR as mediating EPO’s tissue-protective, anti-inflammatory, and cell-protective effects. ARA-290 was developed to selectively activate the IRR without engaging the blood-forming receptor. Brines et al., 2004

Does ARA-290 increase red blood cell counts?

That was not observed in the studies described. ARA-290 was specifically designed not to activate the blood-forming pathway. It is intended to bind to the EPOR/βcR heterodimer—the innate repair receptor—rather than the homodimeric EPO receptor that stimulates red blood cell production.

Blood measures assessed in phase 2 studies of people with sarcoidosis remained stable during treatment. This supports the design principle but does not establish general safety at every dose or with long-term use.

What did the ARA-290 clinical studies find?

The small sarcoidosis studies found positive signals on some symptom questionnaires and structural corneal nerve measurements. In Dahan and colleagues’ 2013 study, the P values for thermal thresholds compared the treatment group with its own baseline, not directly with placebo. Not all pain measures differed between groups. Source 1

In the phase 2b study of 64 people, the 4-mg dose increased corneal nerve fiber area relative to placebo, and more regenerating skin nerve fibers were observed. However, the reported pain difference in the subgroup with moderate to severe pain was not statistically significant (P = .157). A structural marker is not the same as demonstrated pain relief. Source 1

The diabetes study reported changes in HbA1c and PainDetect symptoms, among other findings. HbA1c was a primary outcome; the positive nerve fiber density finding came from a post hoc subgroup analysis. Larger confirmatory studies are still needed. Source 1

Can a doctor prescribe ARA-290?

An ordinary prescription does not turn ARA-290 into an approved treatment. Cibinetide is in Category 3 of the FDA 503A list checked here, and orphan designation is not approval. A credible access route for a particular preparation would need regulatory, legal, and quality assessment.

The sources available here do not establish the current status of every IND. This article therefore does not claim that every possible physician-supervised or research access route is impossible. U.S. regulatory information also does not automatically apply to other countries.

Has ARA-290 development stopped?

The source material alleged that Araim Pharmaceuticals closed in April 2026 for financial or organizational reasons. The primary sources checked here could not confirm that account, so it is not presented as fact. Published phase 2 studies document a stage of research; they do not establish every aspect of the company’s activities today.

The scientific rationale for the IRR and existing findings remain relevant regardless of possible changes at the developer. Whether an active program exists or another sponsor takes it over requires current company and registry information. An older review cannot answer that question.

What is sarcoidosis-associated small fiber neuropathy?

Sarcoidosis is a systemic inflammatory disease in which clusters of inflammatory cells form in different organs. The lungs and lymph nodes are particularly common sites.

Some people with sarcoidosis develop small fiber neuropathy. This damages small peripheral nerve fibers with little or no myelin. It can cause neuropathic pain, burning, and autonomic symptoms—problems with bodily functions that operate without conscious control.

Standard nerve conduction tests mainly assess large nerve fibers and can therefore be normal despite SFN. Sarcoidosis-associated SFN was a principal focus of the clinical ARA-290 program. The IRR is expressed in small nerve fiber tissue, while the drug treatments described in the underlying literature largely aim to relieve symptoms.

The studies discussed here help explain the research on an experimental compound. They do not replace individual diagnosis or treatment and are not instructions for self-administration.

References

The further-reading articles on alpha-lipoic acid for neuropathy and metabolic health are editorial articles, not original studies.

  • PubChem (National Library of Medicine). (n.d.). Gardimycin. https://pubchem.ncbi.nlm.nih.gov/compound/16132310 Note: This retained reference concerns a different compound and does not establish the identity of ARA-290. Cibinetide is listed under CID 91810664.

  • Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, … Brines M (2004). Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science (New York, N.Y.), 305(5681), 239-42. https://doi.org/10.1126/science.1098313 — PubMed

  • Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, Erbayraktar Z, Erbayraktar S, Sepodes B, Thiemermann C, Ghezzi P, Yamin M, Hand CC, Xie QW, Coleman T, Cerami A (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10925-30. https://doi.org/10.1073/pnas.0805594105 — PubMed

  • Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, Latini R, Xie QW, Smart J, Su-Rick CJ, Pobre E, Diaz D, Gomez D, Hand C, Coleman T, Cerami A (2004). Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proceedings of the National Academy of Sciences of the United States of America, 101(41), 14907-12. https://doi.org/10.1073/pnas.0406491101 — PubMed

  • Brines M, Cerami A (2012). The receptor that tames the innate immune response. Molecular medicine (Cambridge, Mass.), 18(1), 486-96. https://doi.org/10.2119/molmed.2011.00414 — PubMed

  • Brines M (2014). Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair. Molecular medicine (Cambridge, Mass.), 20 Suppl 1(Suppl 1), S10-6. https://doi.org/10.2119/molmed.2014.00167 — PubMed

  • Collino M, Thiemermann C, Cerami A, Brines M (2015). Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacology & therapeutics, 151, 32-40. https://doi.org/10.1016/j.pharmthera.2015.02.005 — PubMed

  • Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A (2014). ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Molecular pain, 10, 13. https://doi.org/10.1186/1744-8069-10-13 — PubMed

  • Swartjes M, Niesters M, Heij L, Dunne A, Aarts L, Hand CC, Kim HS, Brines M, Cerami A, Dahan A (2013). Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131). PloS one, 8(8), e71326. https://doi.org/10.1371/journal.pone.0071326 — PubMed

  • Zhang W, Yu G, Zhang M (2016). ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides, 76, 73-9. https://doi.org/10.1016/j.peptides.2016.01.003 — PubMed

  • Heij L, Dahan A, Hoitsma E (2012). Sarcoidosis and pain caused by small-fiber neuropathy. Pain research and treatment, 2012, 256024. https://doi.org/10.1155/2012/256024 — PubMed

  • Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular medicine (Cambridge, Mass.), 18(1), 1430-6. https://doi.org/10.2119/molmed.2012.00332 — PubMed

  • van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M (2014). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert opinion on investigational drugs, 23(4), 541-50. https://doi.org/10.1517/13543784.2014.892072 — PubMed

  • Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular medicine (Cambridge, Mass.), 19(1), 334-45. https://doi.org/10.2119/molmed.2013.00122 — PubMed

  • Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M (2017). Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative ophthalmology & visual science, 58(6), BIO52-BIO60. https://doi.org/10.1167/iovs.16-21291 — PubMed

  • Brines M, Culver DA, Ferdousi M, Tannemaat MR, van Velzen M, Dahan A, Malik RA (2018). Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy. Scientific reports, 8(1), 4734. https://doi.org/10.1038/s41598-018-23107-w — PubMed

  • Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A (2015). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular medicine (Cambridge, Mass.), 20(1), 658-66. https://doi.org/10.2119/molmed.2014.00215 — PubMed

  • Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, Campbell C, Kirk RI, Bajorunas D, Dunne A, Cerami A, Brines M (2020). A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 9(7). https://doi.org/10.3390/jcm9072225 — PubMed

  • van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Jespersen B, Ottens PJ, Ploeg RJ, Leuvenink HG (2013). ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. Journal of translational medicine, 11, 9. https://doi.org/10.1186/1479-5876-11-9 — PubMed

  • van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Ottens PJ, Ploeg RJ, Leuvenink HG (2013). Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury. Journal of translational medicine, 11, 286. https://doi.org/10.1186/1479-5876-11-286 — PubMed

  • Ghassemi-Barghi N, Ehsanfar Z, Mohammadrezakhani O, Ashari S, Ghiabi S, Bayrami Z (2023). Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 46(1), 342-358. https://doi.org/10.1007/s10753-022-01737-7 — PubMed

  • Winicki NM, Nanavati AP, Morrell CH, Moen JM, Axsom JE, Krawczyk M, Petrashevskaya NN, Beyman MG, Ramirez C, Alfaras I, Mitchell SJ, Juhaszova M, Riordon DR, Wang M, Zhang J, Cerami A, Brines M, Sollott SJ, de Cabo R, Lakatta EG (2022). A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan. Frontiers in cardiovascular medicine, 9, 1096887. https://doi.org/10.3389/fcvm.2022.1096887 — PubMed

  • Nairz M, Haschka D, Dichtl S, Sonnweber T, Schroll A, Aßhoff M, Mindur JE, Moser PL, Wolf D, Swirski FK, Theurl I, Cerami A, Brines M, Weiss G (2017). Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. Scientific reports, 7(1), 13012. https://doi.org/10.1038/s41598-017-13046-3 — PubMed

  • Wang RL, Yang ZH, Huang YY, Hu Y, Wang YL, Yan F, Zheng YM, Han ZP, Fan JF, Tao Z, Zhao HP, Li SJ, Luo YM (2024). Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS neuroscience & therapeutics, 30(3), e14676. https://doi.org/10.1111/cns.14676 — PubMed

  • Liu Y, Luo B, Han F, Li X, Xiong J, Jiang M, Yang X, Wu Y, Zhang Z (2014). Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection. PloS one, 9(3), e90942. https://doi.org/10.1371/journal.pone.0090942 — PubMed

  • Chen H, Luo B, Yang X, Xiong J, Liu Z, Jiang M, Shi R, Yan C, Wu Y, Zhang Z (2014). Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. Journal of neuroimmunology, 268(1-2), 64-70. https://doi.org/10.1016/j.jneuroim.2014.01.006 — PubMed

  • Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, Arcoraci V, Aliquò F, Minutoli L, Colonna MR, Galeano MR, Brines M, De Ponte C, Collino M, Squadrito F, Altavilla D (2018). Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. Biochimica et biophysica acta. Molecular basis of disease, 1864(2), 632-639. https://doi.org/10.1016/j.bbadis.2017.12.006 — PubMed

  • Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Kumagai-Braesch M (2016). A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation, 100(3), 554-62. https://doi.org/10.1097/TP.0000000000001026 — PubMed

  • Yao M, Watanabe M, Sun S, Tokodai K, Cerami A, Brines M, Östenson CG, Ericzon BG, Lundgren T, Kumagai-Braesch M (2020). Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand. Transplantation, 104(10), 2048-2058. https://doi.org/10.1097/TP.0000000000003284 — PubMed

  • Dahan A, Brines M, Niesters M, Cerami A, van Velzen M (2016). Targeting the innate repair receptor to treat neuropathy. Pain reports, 1(1), e566. https://doi.org/10.1097/PR9.0000000000000566 — PubMed

  • Cerit H, Veer IM, Dahan A, Niesters M, Harmer CJ, Miskowiak KW, Rombouts SA, Van der Does W (2015). Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 25(12), 2289-99. https://doi.org/10.1016/j.euroneuro.2015.09.005 — PubMed

  • U.S. Food and Drug Administration (2026). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026). https://www.fda.gov/media/94155/download